In recent years, several radioligands targeting prostate-specific membrane antigen (PSMA)
have been clinically introduced as a new class of theranostic radiopharmaceuticals for the …

Objectives PSMA (prostate-specific membrane antigen) is overexpressed in prostate cancer
cells and is reported to be a promising target for antibody-based radioligand therapy in …

Increased abundance of the prostate-specific membrane antigen (PSMA) on prostate
epithelium is a hallmark of advanced metastatic prostate cancer (PCa) and correlates …

There is increasing interest in PET/CT with prostate-specific membrane antigen (PSMA)
tracers for imaging of prostate cancer because of the higher detection rates of prostate …

Aims PSMA (prostate specific membrane antigen) is physiologically expressed in normal
prostate tissue. It is overexpressed in prostate cancer cells and has been suggested as a …

The main barrier to the development of an effective RNA interference (RNAi) therapy is the
lack of a suitable delivery vector. Modified cyclodextrins have emerged in recent years for …

Here, we report that it's feasible for imaging gastric adenocarcinoma mice model with
prostate-specific membrane antigen (PSMA) targeting imaging agents, which could …

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and the
expression increases with tumor aggressiveness, metastatic disease, and recurrence …

Glutamate carboxypeptidase II (GCPII), also known as prostate‐specific membrane antigen
(PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human …

Aims. Expression of PSMA (prostate‐specific membrane antigen) has been demonstrated in
various cancers, including pancreatic ductal adenocarcinoma (PDAC). However, PSMA …